Who is sponsoring NCT03902041?

NCT03902041 is sponsored by Shandong Provincial Hospital.

What drugs are being tested in NCT03902041?

Interventions in NCT03902041: Eltrombopag.

What condition does NCT03902041 study?

NCT03902041 studies Allogeneic Hematopoietic Stem Cell Transplantation, Eltrombopag.

Is NCT03902041 still recruiting?

NCT03902041 is currently status unknown. Last updated 3 April 2019.

Last reviewed 2019-04-03 · How we verify

NCT03902041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT

Status unknown Last updated 3 April 2019

What this trial tests

trial testing Eltrombopag in Allogeneic Hematopoietic Stem Cell Transplantation in 160 participants. Status unknown.

Timeline

1 May 2019

Primary endpoint
30 April 2022

1 October 2022

Quick facts

Lead sponsor	Shandong Provincial Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	160
Start date	1 May 2019
Primary completion	30 April 2022
Estimated completion	1 October 2022
Sites	1 location across China

Drugs / interventions tested

Eltrombopag (ELTROMBOPAG) — full drug profile →

Conditions studied

Allogeneic Hematopoietic Stem Cell Transplantation — all drugs for Allogeneic Hematopoietic Stem Cell Transplantation →
Eltrombopag — all drugs for Eltrombopag →

Sponsor

Shandong Provincial Hospital

Who can join

Adults 18 to 60, any sex, with Allogeneic Hematopoietic Stem Cell Transplantation or Eltrombopag. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the addition of Eltrombopag after Hematopoietic stem cell transplantation (HSCT) to improve the engraftment of hematopoietic stem cell. Half of the participants will receive Eltrombopag,while the other will not receive the Eltrombopag.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.
Bortolotti M, Pettine L, Zaninoni A, Croci GA, et al · · 2022 · cited 6× · PMID 35455416 · DOI 10.3390/ph15040419

Verify or expand the search:

Other trials of Eltrombopag

Trials testing the same drug.

NCT07189910 — Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP · Phase 4 · not yet recruiting
NCT07113743 — Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease · Phase 1, PHASE2 · enrolling by invitation
NCT07093606 — Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura · NA · recruiting
NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
NCT05653219 — A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia · Phase 3 · active not recruiting

Other recruiting trials for Allogeneic Hematopoietic Stem Cell Transplantation

Currently open trials in the same condition.

NCT07013370 — Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H · recruiting
NCT07094464 — Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation · Phase 1 · active not recruiting
NCT06708130 — Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study · recruiting
NCT03357172 — Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transpl · NA · recruiting

Other Shandong Provincial Hospital trials

Trials by the same sponsor.

NCT07333287 — A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With A · Phase 2 · not yet recruiting
NCT07180342 — An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorde · NA · recruiting
NCT07284992 — SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC · Phase 2 · recruiting
NCT06908382 — Neoadjuvant QL1706 Therapy for ESCC · Phase 2 · recruiting
NCT06829797 — A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemothera · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03902041 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong Provincial Hospital
Last refreshed: 3 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03902041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing